Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract Carcinoma
Clinical trial NCT05822453 · UNKNOWN
Trial details
- NCT number
- NCT05822453
- Sponsor
- Peking Union Medical College Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-30
- Primary completion
- 2025-04-30
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.